Deliver gene editing machinery in the form of mRNA, plasmids or ribonuclear proteins (RNPs) for a variety of nucleases and/or nickases including CRISPR, TALENs and ZFN, to primary cells, iPSCs or cell lines using MaxCyte cell engineering for high efficiency gene knock-in, knockout, correction of genetic disease mutations, or generation of custom bioproduction manufacturing cell lines.
Over 15 years ago we developed a non-viral delivery platform for cell-engineering that fulfilled the stringent demands of clinical use, including the ability to reproducibly modify primary human cells with high efficiency and low cytotoxicity. Today, these attributes enable the engineering of primary and stem cells for a variety of clinical and research applications.
Accelerating the Discovery, Development and Manufacturing of Cell-based Medicines
We pioneered the development of a non-viral cell-engineering platform more than 16 years ago for the delivery of biomolecules that fulfills the stringent demands of clinical use – namely the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. Today, our delivery platform is making cell and gene therapy a reality.
The only cell-engineering solution that scales from bench to bedside
Generates cell therapies with enhanced potency and efficacy
Increased safety with minimal toxicity
Clear regulatory pathway for streamlined development
- One commercial immunotherapy, 70+ licenses for clinical development & 100+ partnered programs
